Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
WHEN AND WHERE DOES A CARRIER OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (ILE88LEU) SHOW THE FIRST SIGNS OF THE DISEASE? DIAGNOSTIC CHALLENGES OF A NOT ONLY CARDIOGENIC MUTATION
Anno:
2024
We present the case of a 58-year-old man with a familiar history (mother affected) positive for ATTR-v (Ile88Leu) amyloidosis. The mother initially had a pure cardiac phenotype and was firstly treated with tafamidis, but progression of the disease to the nervous system warranted a switch to patisiran. Our patient…
Leggi di più
DIASTOLIC DYSFUNCTION EVALUATION IN CARDIAC AMYLOIDOSIS: BEYOND TRADITIONAL PARAMETERS TO DISCRIMINATE BETWEEN TRUE HEART FAILURE WITH PRESERVED EJECTION FRACTION AND MIMICS
Anno:
2024
BACKGROUND Diastolic dysfunction in cardiac amyloidosis (CA), according to current guidelines, can be classified using mitral flow velocities, mitral annular e’ velocity, E/e’ ratio, tricuspid regurgitation jet and left atrial (LA) maximal volume. However, LA minimal volume and the ratio between LA and left ventricular (LV) volumes at end-diastole,…
Leggi di più
Transtyretin cardiac amyloidosis in elderly patients: always a wild type?
Anno:
2024
Background: Transthyretin amyloidosis (ATTR) exists in two forms: a genetic form transmitted by autosomal dominant inheritance (ATTRv) and a wild type form (ATTRwt). Clinically, the hereditary form tends to have an early onset in adulthood and it is characterized by a particular tropism for nervous as well as cardiac…
Leggi di più
Role of endomyocardial biopsy in asymptomatic carriers of Transthyretin mutation: a case report.
Anno:
2024
Introduction: There are two forms of cardiac amyloidosis (ATTR-CM) from Transthyretin, one wild-type (ATTRwt) and one hereditary (ATTRv), with autosomal dominant transmission. The introduction of new specific therapies has made it possible to block the progression of the disease. The success of these therapies is mainly linked to the…
Leggi di più
DON’T FORGET ABOUT CARDIAC AMYLOIDOSIS: WHEN RED FLAGS MATTER
Anno:
2024
Case report: a 78-year-old man came to our attention for worsening dyspnea, asthenia and frequent lipothymic episodes in the last few weeks. Nothing remarkable was reported in anamnesis except for periodic cardiological check-ups ascribed to hypertensive heart disease and moderate aortic stenosis. Other cardiovascular risk factors were obesity, previous…
Leggi di più
Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis in Elderly Subjects from the General Population
Anno:
2024
Background: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) affects older adults, and is currently considered as a rare disorder. Objective: We investigated for the first time the prevalence of ATTRwt-CA in elderly individuals from the general population. Methods: General practitioners from Pisa, Italy, proposed a screening for ATTRwt-CA to all their…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Cookie Policy Privacy Policy

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram